These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16225076)

  • 21. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
    Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug discrimination in human post-addicts: agonist/antagonist opioids.
    Preston K; Bigelow G; Bickel W; Liebson I
    NIDA Res Monogr; 1988; 81():209-15. PubMed ID: 2457160
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparing overdose mortality associated with methadone and buprenorphine treatment.
    Bell JR; Butler B; Lawrance A; Batey R; Salmelainen P
    Drug Alcohol Depend; 2009 Sep; 104(1-2):73-7. PubMed ID: 19443138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life among heroin users on buprenorphine versus methadone maintenance.
    Ponizovsky AM; Grinshpoon A
    Am J Drug Alcohol Abuse; 2007; 33(5):631-42. PubMed ID: 17891656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies.
    Pirastu R; Fais R; Messina M; Bini V; Spiga S; Falconieri D; Diana M
    Drug Alcohol Depend; 2006 Jun; 83(2):163-8. PubMed ID: 16343811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.
    Lott DC; Strain EC; Brooner RK; Bigelow GE; Johnson RE
    J Subst Abuse Treat; 2006 Sep; 31(2):187-94. PubMed ID: 16919747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interactions with methadone and buprenorphine].
    Bakke E; Bachs L
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2364-6. PubMed ID: 19935937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preliminary research on opioid mutagenicity].
    Gorazd M; Kamenczak A; Pach J; Schmager J; Wronka I
    Przegl Lek; 2003; 60(4):245-8. PubMed ID: 14569893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of buprenorphine and benzodiazepines on respiration in the rat.
    Nielsen S; Taylor DA
    Drug Alcohol Depend; 2005 Jul; 79(1):95-101. PubMed ID: 15943948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED; Horton T; Reinke K; Amass L; Nunes EV
    J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
    Maremmani I; Pani PP; Pacini M; Perugi G
    J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caring for patients with opioid dependence.
    Bunker J; Winstock A; Zwar NA
    Aust Fam Physician; 2008; 37(1-2):57-60. PubMed ID: 18239755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.